Literature DB >> 8819579

HIV-1 neutralization: the consequences of viral adaptation to growth on transformed T cells.

J P Moore1, D D Ho.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 8819579

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  95 in total

1.  Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers.

Authors:  X Yang; R Wyatt; J Sodroski
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

2.  Variable-loop-deleted variants of the human immunodeficiency virus type 1 envelope glycoprotein can be stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits.

Authors:  R W Sanders; L Schiffner; A Master; F Kajumo; Y Guo; T Dragic; J P Moore; J M Binley
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

3.  Energetics of the HIV gp120-CD4 binding reaction.

Authors:  D G Myszka; R W Sweet; P Hensley; M Brigham-Burke; P D Kwong; W A Hendrickson; R Wyatt; J Sodroski; M L Doyle
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-01       Impact factor: 11.205

4.  Feline immunodeficiency virus-infected cat sera associated with the development of broad neutralization resistance in vivo drive similar reversions in vitro.

Authors:  S Giannecchini; D Matteucci; A Ferrari; M Pistello; M Bendinelli
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

5.  Neutralizing antibodies against autologous human immunodeficiency virus Type 1 isolates in patients with increasing CD4 cell counts despite incomplete virus suppression during antiretroviral treatment.

Authors:  L Sarmati; G d'Ettorre; E Nicastri; L Ercoli; I Uccella; P Massetti; S G Parisi; V Vullo; M Andreoni
Journal:  Clin Diagn Lab Immunol       Date:  2001-07

Review 6.  Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development.

Authors:  J P Moore; P W Parren; D R Burton
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

Review 7.  HIV vaccine development at Duke University Medical Center.

Authors:  B F Haynes; H X Liao; H F Staats; M S Alam; K J Weinhold; D C Montefiori
Journal:  Immunol Res       Date:  2000       Impact factor: 2.829

8.  Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization.

Authors:  Bimal K Chakrabarti; Wing-pui Kong; Bei-yue Wu; Zhi-Yong Yang; Jacques Friborg; Xu Ling; Steven R King; David C Montefiori; Gary J Nabel
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

9.  During readaptation in vivo, a tissue culture-adapted strain of feline immunodeficiency virus reverts to broad neutralization resistance at different times in individual hosts but through changes at the same position of the surface glycoprotein.

Authors:  M Bendinelli; M Pistello; D Del Mauro; G Cammarota; F Maggi; A Leonildi; S Giannecchini; C Bergamini; D Matteucci
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

10.  Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design.

Authors:  Ralph Pantophlet; Ian A Wilson; Dennis R Burton
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.